Overcoming key biological barriers to cancer drug delivery and efficacy
- 13 September 2017
- journal article
- review article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 267, 15-30
- https://doi.org/10.1016/j.jconrel.2017.09.016
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (U01CA193787, R01CA169644)
This publication has 140 references indexed in Scilit:
- Vessel co‐option in primary human tumors and metastases: an obstacle to effective anti‐angiogenic treatment?Cancer Medicine, 2013
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lungNature Biotechnology, 2007
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993